Bluebird Bio, Inc. (NASDAQ: BLUE) was founded in 1992, formerly known as Genetix Pharmaceuticals, Inc., changed to its current name in September 2010, headquartered in Cambridge, Massachusetts, USA, with 479 full-time employees , Is a clinical stage biotechnology company dedicated to the development of revolutionary gene therapy for the treatment of serious genetic diseases and rare diseases.
BLUEBIRD BIO (BLUE):
Bluebird Bio is a clinical-stage biotechnology company focused on developing transformational gene therapies for serious genetic diseases and cancer.
Company candidate products include :
1. Lenti-D -used to treat children with cerebral adrenal leukodystrophy (a rare genetic neurological disease in boys), currently in phase II/III clinical trials.
2. LentiGlobin -used to treat transfusion-dependent β-thalassemia and severe sickle cell disease (SCD). It is in multiple clinical research stages, including Europe and the United States.
3. The main candidate products in the oncology field include bb2121 and bb21217 -which are anti-B cell maturation antigens and are currently in the phase I clinical stage for the treatment of relapsed/refractory multiple myeloma.
4. A variety of CAR T cell products -treatment of liquid and solid tumors/cancers.
bluebird bio has a strategic partnership with Celgene Corporation to discover, develop and commercialize tumor disease transformation gene therapy; has a partnership with Medigene AG to research and develop T cell receptor candidates for antigens for the treatment of cancer indications; and TC BioPharm Limited cooperates in the research and development of γδ chimeric antigen receptor-modified T cell candidates for cancer immunotherapy; and a cooperation agreement with Celgene European Investment Company LLC.
BLUEBIRD BIO (BLUE) investment:
When we introduced JUNO earlier, we mentioned that the short-term stock prices of BLUE and KITE may be affected by NVS ‘s CAR-T curative effect that is not up to expectations, but they are optimistic in the long-term.